TOP HEADLINES

Featured Story

  • UPenn researchers develop nanogel for mitigating lung inflammation

    Researchers at the University of Pennsylvania said they have uncovered a delivery method to treat acute pulmonary inflammation, a condition that afflicts patients suffering from multiple blood transfusions, sepsis, lung surgery and acute lung trauma and has a mortality rate as high as 40%.

Nature-inspired artificial cilia could help move drugs to a target

Like the tiny organelles used to propel some bacteria, artificial cilia developed by German engineers could someday help deliver drugs.

Developer of unique delivery technology for eye care expanding in Europe

Oraya Therapeutics, the developer of a low energy X-ray beam that can safely deliver radiation therapy to the into the eye, is expanding its presence in Europe. The 20-minute one-time procedure is designed to reduce the need for anti-vascular endothelial growth factor injections in patients with wet age-related macular degeneration.

Nanoparticles deliver agents to spur immune system into action against cancer

Researchers have found a way to use nanoparticles to deliver drugs that can "wake up" the immune system and fortify its natural response to harmful cancer cells in the body.

Amid fears of antibiotics shortage, DNA origami technique developed to combat E. coli, other bugs

Researchers at the National University of Singapore have developed a method for delivering the polypeptide antibiotic actinomycin D with modified, self-assembled DNA nanopyramid against bacteria such as E. coli and Staphylococcus aureus, the bug causes staph infections.

AcelRx discusses sublingual painkiller's rejection with concerned investors

On the heels of FDA's rejection of the AcelRx New Drug Application for sublingually delivered postoperative pain killer Zalviso, CEO Richard King expounded on the "optical system errors" of the opioid drug's handheld, preprogrammed delivery device during a July 28 conference call with investors.  

MORE NEWS

From Our Sister Sites

FierceBiotech

In this week's EuroBiotech Report, the last week of July was a massive one for European biotech IPOs, with BioBlast Pharma, Innocoll, Macrocure, Mapi Pharma and VBL Therapeutics all heading to the Nasdaq. All of the companies struggled though. And more.

FierceMedicalDevices

HeartWare International is facing FDA ire for its ventricular assist system, but regulatory pushback hasn't seemed to put a damper on earnings. The company charted double-digit growth during the second quarter, fueled in part by record sales for its signature device in domestic and international markets.